Copley Acquisition Corp (NYSE:COPL) ("Copley"), a special purpose acquisition company and Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"), a leader in pathway-level protein analytics to guide precision oncology, announced today that they have entered into a definitive business combination agreement ("BCA").

Upon the closing of the Combination, Copley and Ignite Proteomics will become wholly owned subsidiaries of a newly formed public holding company, which we intend to name Ignite Proteomics Holdings, Inc. ("PubCo"), and which will be listed on the New York Stock Exchange.

"We are thrilled to partner with the team at Ignite Proteomics," said Chibo Tang, Co-Chief Executive Officer of Copley Acquisition Corp. "After an extensive search for a high-impact partner, it became clear that Ignite's innovation represents a fundamental shift in how we understand and treat disease. We believe this transaction will provide Ignite with the runway and public platform required to deliver on its mission to revolutionize precision medicine."

"This transaction represents an exceptionally disciplined entry point into the precision oncology sector," said Francis Ng, Co-Chief Executive Officer of Copley Acquisition Corp. "At a $150 million pro forma enterprise value, we are bringing Ignite to the public markets at a highly attractive valuation. Combined with our management team's stellar capital market track records, we believe the post-closing balance sheet will be optimized to aggressively scale commercial infrastructure and capture a significant share of an addressable market expected to see impressive growth over the next decade."

"Partnering with Copley marks a pivotal milestone for Ignite Proteomics," said Jeffrey Busch, Chief Executive Officer of Ignite Proteomics. "This transaction validates the technology we have spent years developing and provides the financial backing to bring our solutions to a broader market. We are eager to enter this next chapter as a public company, focused on driving long-term value for our shareholders and, most importantly, for the researchers and patients who rely on advanced proteomics."

The proposed Combination is expected to close in the second half of 2026, subject to customary closing conditions.